GlassScriptPhysician profile
Byron S Decamp
NPI 1306040092
$104,164.40
in general payments reported to CMS, 2019-2025
21 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $429 · 2021: $9,028 · 2022: $1,211 · 2023: $1,962 · 2024: $26K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Travel and Lodging: $11K · Food and Beverage: $7,360 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $57,010.09 |
| Travel and Lodging | $11,343.76 |
| Food and Beverage | $7,360.48 |
| Education | $321.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $92,612.31 | 2019-2025 | Tr Band, Navicross, Glidesheath Slender |
| W. L. Gore & Associates, INC. | $3,171.17 | 2019-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Excluder Aaa Endoprosthesis |
| Endologix LLC | $2,783.47 | 2022-2024 | Alto Abdominal Stent Graft System, Torus Stent Graft System, Endocross Device |
| Medtronic, INC. | $1,032.01 | 2021-2025 | Hawkone, Endurant Iis, In.Pact Admiral |
| Bolton Medical INC | $996.47 | 2021-2023 | Treo Abdominal Stent-Graft System |
| Silk Road Medical, INC. | $944.93 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Penumbra, INC. | $524.82 | 2020-2025 | Penumbra System, Indigo System, Ruby Coil |
| Medtronic Vascular, INC. | $515.09 | 2019-2020 | |
| Lemaitre Vascular, INC. | $475.19 | 2022-2025 | Artegraft Vascular Graft, Tyke, Patch, Pledget and Intracardiac, Hydro Lemaitre Valvulotome |
| Shockwave Medical, INC | $239.77 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Aroa Biosurgery Incorporated | $205.43 | 2024-2025 | |
| Microvention, INC. | $180.61 | 2025 | |
| Surmodics, INC. | $157.18 | 2025 | Pounce Thrombectomy System, Pounce LP Thrombectomy, Pounce Xl Thrombectomy |
| Boston Scientific Corporation | $144.89 | 2019-2025 | Enroute Transcarotid Stent, Eluvia |
| Abbott Laboratories | $60.66 | 2023-2025 | Esprit, Jeti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.53 | 2022-2024 | Xarelto |
| Stryker Corporation | $23.31 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $17.77 | 2022 | |
| Centerline Biomedical INC. | $15.96 | 2022 | |
| Getinge USA Sales, LLC | $15.05 | 2021 | |
| Cook Medical LLC | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Decamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.